|
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: The ANZUP ENZARAD Trial (ANZUP 1303). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - BIND Biosciences; Leuchemix |
Consulting or Advisory Role - Astellas Pharma; Bayer; BIND Biosciences; Genentech/Roche; Janssen Biotech; Sanofi |
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Janssen Biotech (Inst) |
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination |
|
|
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bionomics (Inst); Celgene (Inst); Medivation (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbott Diagnostics (I); GenomeDx; Medivation |
Patents, Royalties, Other Intellectual Property - Wife has a patent on volatile diagnostics of infections (I) |